|
|
Takeda
Oncology is the brand for the global oncology business unit of Takeda
Pharmaceutical Company Limited. We aspire to cure cancer by
delivering novel medicines to meet the unique and urgent needs of
people living with cancer, their loved ones and the health care
providers who support them around the world. Additional information
about Takeda Oncology is available at www.takedaoncology.com
|
|
Amgen
is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing,
manufacturing and delivering innovative human therapeutics. This
approach begins by using tools like advanced human genetics to
unravel the complexities of disease and understand the fundamentals
of human biology.
Amgen
focuses on areas of high unmet medical need and leverages its
biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline of
medicines with breakaway potential. For more information, visit:
www.amgen.com
and
follow us on: www.twitter.com/amgen
|
|
Celgene
is a global biopharmaceutical company committed to improving the
lives of patients worldwide. We seek to deliver truly innovative and
life-changing drugs for our patients through the discovery,
development, and commercialization of products for cancer and other
severe, immune, inflammatory conditions. Celgene employs more than
5,300 employees worldwide. Visit: www.celgene.com
|
|
Janssen
Pharmaceutical Companies of Johnson & Johnson are dedicated to
addressing and solving the most important unmet medical needs of our
time, incl. oncology, immunology, neuroscience, infectious disease
and cardiovascular and metabolic diseases. Driven by our commitment
to patients, we develop sustainable, integrated healthcare solutions
by working side-by-side with healthcare stakeholders.. More info on
www.janssen-emea.com
|
|
Novartis
provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs:
innovative medicines, eye care and cost-saving generic
pharmaceuticals. Novartis is the only global company with leading
positions in these areas. In 2015, the Group achieved net sales of
USD 49.4 billion, while R&D throughout the Group amounted to
approximately USD 8.9 billion (USD 8.7 billion excluding impairment
and amortization charges). Novartis Group companies employ
approximately 119,000 full-time-equivalent associates. Novartis
products are available in more than 180 countries around the world.
For more information, please visit http://www.novartis.com
|
 |
Neopharm
Israel is dedicated to bringing solutions to patients suffering from
life-threatening diseases with unmet medical needs around the world,
while creating maximum value for our patients, customers, business
partners, employees and shareholders. For more information, please visit: www.neopharmisrael.com
|
|
Neovii
is an independent, global biopharmaceutical company with a
patient-focused mission to develop and bring to market novel
life-transforming therapies to improve the outcomes in
transplantation medicine, hemato-oncological and immune disorders.
Neovii was founded in 2013 by te acquisition of Fresenius Biotech
inheriting more than three decades of experience in speciality
pharmaecuticals. Neovii's global headquarters are located in
Rapperswil, Switzerland, its U.S headquarters are in Waltham, MA, and
its biologics manufacturing site and German operations are located in
Gräfelfing, Germany. Neovii employs approx. 150 employees and has
presence in nearly 60 countries worldwide. Visit:
www.neovii.com
|
|
Sigma-tau
Research Switzerland S.A. (Mendrisio, CH) is actively engaged in the
development of innovative treatments for rare diseases. More
specifically in the hematologic malignancies arena, sigma-tau
Research Switzerland is developing Roneparstat (SST0001), a
microenvironment modulator via the specific inhibition of the enzyme
heparanase currently completing phase I, as a new potential
therapeutic agent for multiple myeloma. Visit: www.sigma-tau.it
|
|
Sanofi,
a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core
strengths in diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and Genzyme.
Sanofi
has a strong heritage in oncology research, and notably in
chemotherapy. Its aim is to combat cancer in all its different forms
by carrying out research on the different pathways involved in the
development, growth and propagation of cancer cells. The oncology R&D
portfolio contains a range of innovative therapeutic agents with
different mechanisms of action. Through collaborations focusing on
novel therapeutic approaches including immuno-oncology, we reinforced
our presence in this area.
Visit: http://en.sanofi.com
|
|
Binding
Site is committed to improving patient lives worldwide through
education, collaboration and innovation. Discover how your Multiple
Myeloma patients could benefit from Binding Site's Freelite®
and Hevylite®
assays and specialist analyers including the new Optilite.
Freelite
is the ONLY serum free light chain test recommended by international
and national guidelines supported by more than 15 years of clinical
evidence. The complimentary 'Hevylite'
test adds additional information for "difficult-to-monitor"
myeloma patients.
Using
Freelite
and Hevylite
together is the best Multiple Myeloma monitoriing system.
VIsit:
www.bindingsite.com
|